Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial

RA Mesa, AM Vannucchi, A Mead, M Egyed, A Szoke, A Suvorov, J Jakucs, A Perkins, R Prasad, J Mayer, J Demeter, P Ganly, JW Singer, HF Zhou, JP Dean, Peter te Boekhorst, J Nangalia, JJ Kiladjian, CN Harrison

Research output: Contribution to journalArticleAcademicpeer-review

145 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)E225-E236
JournalLancet Haematology
Issue number5
Publication statusPublished - 2017

Cite this